Top ▲

Y5 receptor

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 308

Nomenclature: Y5 receptor

Family: Neuropeptide Y receptors

Gene and Protein Information Click here for help
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 445 4q32.2 NPY5R neuropeptide Y receptor Y5 4,16
Mouse 7 466 8 33.15 cM Npy5r neuropeptide Y receptor Y5 4,28
Rat 7 445 16p14 Npy5r neuropeptide Y receptor Y5 12,16
Previous and Unofficial Names Click here for help
food intake receptor | neuropeptide Y receptor type 5
Database Links Click here for help
Specialist databases
GPCRdb npy5r_human (Hs), npy5r_mouse (Mm), npy5r_rat (Rn)
Other databases
Alphafold
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Natural/Endogenous Ligands Click here for help
neuropeptide Y {Sp: Human, Mouse, Rat}
pancreatic polypeptide {Sp: Human} , pancreatic polypeptide {Sp: Mouse} , pancreatic polypeptide {Sp: Rat}
peptide YY {Sp: Human} , peptide YY {Sp: Mouse, Rat, Pig}
PYY-(3-36) {Sp: Mouse, Rat}
Comments: Neuropeptide Y is the principal endogenous agonist
Potency order of endogenous ligands (Human)
neuropeptide Y > peptide YY > pancreatic polypeptide

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP Peptide Ligand is labelled Ligand is radioactive Rn Agonist 9.2 – 9.3 pKd 10
pKd 9.2 – 9.3 (Kd 7x10-10 – 5x10-10 M) [10]
[125I][PP1-17,Ala31,Aib32]NPY (human) Peptide Ligand is labelled Ligand is radioactive Rn Full agonist 8.9 pKd 9
pKd 8.9 [9]
neuropeptide Y {Sp: Human, Mouse, Rat} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Rn Full agonist 9.3 pKi 16
pKi 9.3 [16]
neuropeptide Y {Sp: Human, Mouse, Rat} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 9.1 pKi 16
pKi 9.1 [16]
[Leu31,Pro34]NPY (pig) Peptide Click here for species-specific activity table Hs Full agonist 9.1 pKi 16
pKi 9.1 [16]
peptide YY {Sp: Mouse, Rat, Pig} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Rn Full agonist 9.0 pKi 16
pKi 9.0 [16]
[Leu31,Pro34]NPY (pig) Peptide Click here for species-specific activity table Rn Full agonist 8.6 – 9.3 pKi 9,16
pKi 8.6 – 9.3 [9,16]
peptide YY {Sp: Mouse, Rat, Pig} Peptide Click here for species-specific activity table Hs Full agonist 8.9 pKi 16
pKi 8.9 [16]
NPY-(2-36) Peptide Click here for species-specific activity table Hs Full agonist 8.9 pKi 16
pKi 8.9 [16]
NPY-(2-36) Peptide Click here for species-specific activity table Rn Full agonist 8.9 pKi 16
pKi 8.9 [16]
pancreatic polypeptide {Sp: Human} Peptide Click here for species-specific activity table Rn Full agonist 8.4 – 9.3 pKi 9,16
pKi 8.4 – 9.3 [9,16]
[Leu31,Pro34]PYY (human) Peptide Click here for species-specific activity table Hs Full agonist 8.8 pKi 16
pKi 8.8 [16]
[PP1-17,Ala31,Aib32]NPY (human) Peptide Hs Full agonist 8.8 pKi 9
pKi 8.8 [9]
NPY-(3-36) (pig) Peptide Click here for species-specific activity table Rn Full agonist 8.7 pKi 16
pKi 8.7 [16]
[Leu31,Pro34]PYY (human) Peptide Click here for species-specific activity table Rn Full agonist 8.7 pKi 16
pKi 8.7 [16]
PYY-(3-36) {Sp: Mouse, Rat} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Rn Full agonist 8.4 pKi 16
pKi 8.4 [16]
[Ala31,Aib32]NPY Peptide Rn Full agonist 8.4 pKi 9
pKi 8.4 [9]
[D-Trp32]NPY Peptide Click here for species-specific activity table Rn Full agonist 8.2 pKi 16
pKi 8.2 [16]
[D-Trp32]NPY Peptide Click here for species-specific activity table Hs Full agonist 8.1 pKi 16
pKi 8.1 [16]
NPY-(3-36) (pig) Peptide Click here for species-specific activity table Hs Full agonist 8.0 pKi 16
pKi 8.0 [16]
pancreatic polypeptide {Sp: Human} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 8.0 pKi 16
pKi 8.0 [16]
PYY-(3-36) {Sp: Mouse, Rat} Peptide Hs Full agonist 8.0 pKi 16
pKi 8.0 [16]
NPY-(13-36) (pig) Peptide Click here for species-specific activity table Rn Full agonist 7.7 pKi 16
pKi 7.7 [16]
NPY-(13-36) (pig) Peptide Click here for species-specific activity table Hs Full agonist 7.3 pKi 16
pKi 7.3 [16]
PYY-(13-36) (mouse, rat, pig) Peptide Click here for species-specific activity table Hs Full agonist 7.1 pKi 16
pKi 7.1 [16]
PYY-(13-36) (mouse, rat, pig) Peptide Click here for species-specific activity table Rn Full agonist 7.1 pKi 16
pKi 7.1 [16]
NPY-(18-36) (human, pig) Peptide Rn Full agonist 6.7 pKi 16
pKi 6.7 [16]
pancreatic polypeptide {Sp: Rat} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Rn Full agonist 6.5 pKi 16
pKi 6.5 [16]
pancreatic polypeptide {Sp: Rat} Peptide Click here for species-specific activity table Hs Full agonist 6.4 pKi 16
pKi 6.4 [16]
GR231118 Peptide Click here for species-specific activity table Rn Full agonist 6.4 pKi 9
pKi 6.4 [9]
NPY-(18-36) (human, pig) Peptide Click here for species-specific activity table Hs Full agonist 6.2 pKi 16
pKi 6.2 [16]
[Ala31,Aib32]NPY (pig) Peptide Click here for species-specific activity table Hs Full agonist 8.2 pIC50 5
pIC50 8.2 [5]
[Ala31,Aib32]NPY (pig) Peptide Rn Full agonist 8.2 pIC50 5
pIC50 8.2 [5]
View species-specific agonist tables
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
CGP 71683A Small molecule or natural product Rn Antagonist 9.5 pKi 9
pKi 9.5 [9]
JCF 109 Small molecule or natural product Rn Antagonist 8.3 pKi 9
pKi 8.3 [9]
L-152,804 Small molecule or natural product Hs Antagonist 7.6 pKi 20
pKi 7.6 [20]
L-152,804 Small molecule or natural product Rn Antagonist 7.5 pKi 20
pKi 7.5 [20]
FMS586 Small molecule or natural product Hs Antagonist 8.4 pIC50 19
pIC50 8.4 [19]
View species-specific antagonist tables
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Immune regulation
Primary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gi/Go family Adenylyl cyclase inhibition
References:  3
Tissue Distribution Click here for help
Ventrolateral portion of the suprachiasmatic nucleus.
Species:  Rat
Technique:  in situ hybridisation.
References:  23
Small intestine (epithelial crypts), colon (nonepithelial tissue).
Species:  Rat
Technique:  RT-PCR.
References:  13
Brain: hippocampus, hypothalamus, cortex, amygdala.
Species:  Rat
Technique:  in situ hybridisation.
References:  29
CNS: olfactory bulb, lateral septum, anteroventral thalamic nucleus, CA3 subfield of the ventral hippocampus, nucleus tractus solitarius, area postrema.
Species:  Rat
Technique:  Radioligand binding.
References:  8
Expression Datasets Click here for help

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays Click here for help
Measurement of cAMP levels in HEK 293 cells transfected with the rat Y5 receptor.
Species:  Rat
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  12
Measurement of cAMP levels in HEK 293 cells transfected with the human Y5 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  19
Measurement of cAMP levels in HEC-1B cells transfected with the human Y5 receptor.
Species:  Human
Tissue:  HEC-1B cells.
Response measured:  Inhibition of cAMP accumulation.
References:  3
Physiological Functions Click here for help
Hyperinsulinemia dependent of food ingestion.
Species:  Rat
Tissue:  In vivo.
References:  11
Modulation of ethanol consumption.
Species:  Rat
Tissue:  In vivo.
References:  33
Modulation of anxiety-related behaviour.
Species:  Rat
Tissue:  In vivo.
References:  34
Sedation.
Species:  Rat
Tissue:  In vivo.
References:  34
Modulation of food intake.
Species:  Rat
Tissue:  In vivo.
References:  6-7,15,17,22,30,32,35,37,39-40
Regulation of the gonadotropic axis.
Species:  Rat
Tissue:  In vivo.
References:  31
Regulation of energy homeostasis.
Species:  Rat
Tissue:  In vivo.
References:  27
Supression of reproduction.
Species:  Rat
Tissue:  In vivo.
References:  36
Physiological Consequences of Altering Gene Expression Click here for help
Y5 receptor knockout mice exhibit more severe systemic kainate-induced seizures compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  38
Y5 receptor knockout mice do not exhibit spontaneous seizure-like activity, but do exhibit an increased sensitivity to kainic acid-induced seizures.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  25
Hippocampal slices from Y5 receptor knockout mice do not exhibit inhibition of excitatory synaptic transmission as seen in slices fromwild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  1,14
Y5 receptor knockout mice do not exhibit an antagonist-induced decrease in diet-induced obesity, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  18
Y5 receptor knockout mice exhibit increases in body weight, food intake and adiposity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  26
Y5 receptor knockout mice exhibit altered Y5 agonist-induced food intake.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  21
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:108082  MP:0001259 abnormal body weight PMID: 9623983 
Lepob|Npy5rtm1Rpa Lepob/Lepob,Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:104663  MGI:108082  MP:0001259 abnormal body weight PMID: 9623983 
Npy5rtm1Aka Npy5rtm1Aka/Npy5rtm1Aka
involves: C57BL/6 * CBA
MGI:108082  MP:0003910 decreased eating behavior PMID: 10698177 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:108082  MP:0002628 hepatic steatosis PMID: 9623983 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd
MGI:108082  MP:0001745 increased circulating corticosterone level PMID: 14525913 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd
MGI:108082  MP:0002079 increased circulating insulin level PMID: 14525913 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd
MGI:108082  MP:0005669 increased circulating leptin level PMID: 14525913 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd
MGI:108082  MP:0009304 increased retroperitoneal fat pad weight PMID: 14525913 
Npy5rtm1Aka Npy5rtm1Aka/Npy5rtm1Aka
involves: C57BL/6 * CBA
MGI:108082  MP:0005658 increased susceptibility to diet-induced obesity PMID: 16636293 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:108082  MP:0010024 increased total body fat amount PMID: 9623983 
Lepob|Npy5rtm1Rpa Lepob/Lepob,Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:104663  MGI:108082  MP:0008908 increased total fat pad weight PMID: 9623983 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:108082  MP:0001261 obese PMID: 9623983 
Lepob|Npy5rtm1Rpa Lepob/Lepob,Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:104663  MGI:108082  MP:0001261 obese PMID: 9623983 
Npy5rtm1Aka Npy5rtm1Aka/Npy5rtm1Aka
involves: C57BL/6 * CBA
MGI:108082  MP:0001261 obese PMID: 10698177 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd
MGI:108082  MP:0001261 obese PMID: 14525913 
Npy5rtm1Rpa Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:108082  MP:0001433 polyphagia PMID: 9623983 
Lepob|Npy5rtm1Rpa Lepob/Lepob,Npy5rtm1Rpa/Npy5rtm1Rpa
involves: 129S7/SvEvBrd * C57BL/6
MGI:104663  MGI:108082  MP:0001433 polyphagia PMID: 9623983 
General Comments
For a review on the functions of Y5 receptors see [2].
For a review on NPY receptor knockout mice see [24].

References

Show »

1. Baraban SC. (2002) Antiepileptic actions of neuropeptide Y in the mouse hippocampus require Y5 receptors. Epilepsia, 43 Suppl 5: 9-13. [PMID:12121287]

2. Bischoff A, Michel MC. (1999) Emerging functions for neuropeptide Y5 receptors. Trends Pharmacol Sci, 20 (3): 104-6. [PMID:10203865]

3. Bischoff A, Püttmann K, Kötting A, Moser C, Buschauer A, Michel MC. (2001) Limited signal transduction repertoire of human Y(5) neuropeptide Y receptors expressed in HEC-1B cells. Peptides, 22 (3): 387-94. [PMID:11287093]

4. Borowsky B, Walker MW, Bard J, Weinshank RL, Laz TM, Vaysse P, Branchek TA, Gerald C. (1998) Molecular biology and pharmacology of multiple NPY Y5 receptor species homologs. Regul Pept, 75-76: 45-53. [PMID:9802393]

5. Cabrele C, Wieland HA, Koglin N, Stidsen C, Beck-Sickinger AG. (2002) Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry, 41 (25): 8043-9. [PMID:12069595]

6. Criscione L, Rigollier P, Batzl-Hartmann C, Rüeger H, Stricker-Krongrad A, Wyss P, Brunner L, Whitebread S, Yamaguchi Y, Gerald C et al.. (1998) Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest, 102 (12): 2136-45. [PMID:9854049]

7. Daniels AJ, Grizzle MK, Wiard RP, Matthews JE, Heyer D. (2002) Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul Pept, 106 (1-3): 47-54. [PMID:12047910]

8. Dumont Y, Fournier A, Quirion R. (1998) Expression and characterization of the neuropeptide Y Y5 receptor subtype in the rat brain. J Neurosci, 18 (15): 5565-74. [PMID:9671648]

9. Dumont Y, Thakur M, Beck-Sickinger A, Fournier A, Quirion R. (2003) Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY. Br J Pharmacol, 139 (7): 1360-8. [PMID:12890716]

10. Dumont Y, Thakur M, Beck-Sickinger A, Fournier A, Quirion R. (2004) Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP. Neuropeptides, 38 (4): 163-74. [PMID:15337369]

11. Gao J, Ghibaudi L, Hwa JJ. (2004) Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms. Am J Physiol Endocrinol Metab, 287 (4): E706-11. [PMID:15187000]

12. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL et al.. (1996) A receptor subtype involved in neuropeptide-Y-induced food intake. Nature, 382 (6587): 168-71. [PMID:8700207]

13. Goumain M, Voisin T, Lorinet AM, Laburthe M. (1998) Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon. Biochem Biophys Res Commun, 247 (1): 52-6. [PMID:9636652]

14. Guo H, Castro PA, Palmiter RD, Baraban SC. (2002) Y5 receptors mediate neuropeptide Y actions at excitatory synapses in area CA3 of the mouse hippocampus. J Neurophysiol, 87 (1): 558-66. [PMID:11784771]

15. Haynes AC, Arch JR, Wilson S, McClue S, Buckingham RE. (1998) Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor?. Regul Pept, 75-76: 355-61. [PMID:9802429]

16. Hu Y, Bloomquist BT, Cornfield LJ, DeCarr LB, Flores-Riveros JR, Friedman L, Jiang P, Lewis-Higgins L, Sadlowski Y, Schaefer J et al.. (1996) Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem, 271 (42): 26315-9. [PMID:8824284]

17. Hwa JJ, Witten MB, Williams P, Ghibaudi L, Gao J, Salisbury BG, Mullins D, Hamud F, Strader CD, Parker EM. (1999) Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am J Physiol, 277 (5): R1428-34. [PMID:10564216]

18. Ishihara A, Kanatani A, Mashiko S, Tanaka T, Hidaka M, Gomori A, Iwaasa H, Murai N, Egashira S, Murai T et al.. (2006) A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci USA, 103 (18): 7154-8. [PMID:16636293]

19. Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, Nakatani Y, Ohsawa F, Nishikawa N, Sugai M et al.. (2006) Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor. J Pharmacol Exp Ther, 317 (2): 562-70. [PMID:16436501]

20. Kanatani A, Ishihara A, Iwaasa H, Nakamura K, Okamoto O, Hidaka M, Ito J, Fukuroda T, MacNeil DJ, Van der Ploeg LH et al.. (2000) L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun, 272 (1): 169-73. [PMID:10872822]

21. Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LH et al.. (2000) Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology, 141 (3): 1011-6. [PMID:10698177]

22. Kask A, Vasar E, Heidmets LT, Allikmets L, Wikberg JE. (2001) Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur J Pharmacol, 414 (2-3): 215-24. [PMID:11239922]

23. Larsen PJ, Kristensen P. (1998) Distribution of neuropeptide Y receptor expression in the rat suprachiasmatic nucleus. Brain Res Mol Brain Res, 60 (1): 69-76. [PMID:9748510]

24. Lin S, Boey D, Herzog H. (2004) NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides, 38 (4): 189-200. [PMID:15337371]

25. Marsh DJ, Baraban SC, Hollopeter G, Palmiter RD. (1999) Role of the Y5 neuropeptide Y receptor in limbic seizures. Proc Natl Acad Sci USA, 96 (23): 13518-23. [PMID:10557353]

26. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. (1998) Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med, 4 (6): 718-21. [PMID:9623983]

27. Mashiko S, Ishihara A, Iwaasa H, Sano H, Oda Z, Ito J, Yumoto M, Okawa M, Suzuki J, Fukuroda T et al.. (2003) Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY. Endocrinology, 144 (5): 1793-801. [PMID:12697685]

28. Nakamura M, Yokoyama M, Watanabe H, Matsumoto T. (1997) Molecular cloning, organization and localization of the gene for the mouse neuropeptide Y-Y5 receptor. Biochim Biophys Acta, 1328 (2): 83-9. [PMID:9315606]

29. Parker RM, Herzog H. (1999) Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci, 11: 1431-1448. [PMID:10103138]

30. Polidori C, Ciccocioppo R, Regoli D, Massi M. (2000) Neuropeptide Y receptor(s) mediating feeding in the rat: characterization with antagonists. Peptides, 21 (1): 29-35. [PMID:10704716]

31. Raposinho PD, Broqua P, Pierroz DD, Hayward A, Dumont Y, Quirion R, Junien JL, Aubert ML. (1999) Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype. Endocrinology, 140 (9): 4046-55. [PMID:10465275]

32. Schaffhauser AO, Stricker-Krongrad A, Brunner L, Cumin F, Gerald C, Whitebread S, Criscione L, Hofbauer KG. (1997) Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides. Diabetes, 46 (11): 1792-8. [PMID:9356028]

33. Schroeder JP, Overstreet DH, Hodge CW. (2005) The neuropeptide-Y Y5 receptor antagonist L-152,804 decreases alcohol self-administration in inbred alcohol-preferring (iP) rats. Alcohol, 36 (3): 179-86. [PMID:16377459]

34. Sørensen G, Lindberg C, Wörtwein G, Bolwig TG, Woldbye DP. (2004) Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J Neurosci Res, 77 (5): 723-9. [PMID:15352219]

35. Tang-Christensen M, Kristensen P, Stidsen CE, Brand CL, Larsen PJ. (1998) Central administration of Y5 receptor antisense decreases spontaneous food intake and attenuates feeding in response to exogenous neuropeptide Y. J Endocrinol, 159: 307-312. [PMID:9795372]

36. Toufexis DJ, Kyriazis D, Woodside B. (2002) Chronic neuropeptide Y Y5 receptor stimulation suppresses reproduction in virgin female and lactating rats. J Neuroendocrinol, 14: 492-497. [PMID:12047724]

37. Turnbull AV, Ellershaw L, Masters DJ, Birtles S, Boyer S, Carroll D, Clarkson P, Loxham SJ, McAulay P, Teague JL et al.. (2002) Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes, 51 (8): 2441-9. [PMID:12145156]

38. Woldbye DP, Nanobashvili A, Sørensen AT, Husum H, Bolwig TG, Sørensen G, Ernfors P, Kokaia M. (2005) Differential suppression of seizures via Y2 and Y5 neuropeptide Y receptors. Neurobiol Dis, 20 (3): 760-72. [PMID:15979311]

39. Wyss P, Levens N, Stricker-Krongrad A. (1998) Stimulation of feeding in lean but not in obese Zucker rats by a selective neuropeptide Y Y5 receptor agonist. Neuroreport, 9 (11): 2675-7. [PMID:9721954]

40. Wyss P, Stricker-Krongrad A, Brunner L, Miller J, Crossthwaite A, Whitebread S, Criscione L. (1998) The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul Pept, 75-76: 363-371. [PMID:9802430]

Contributors

Show »

How to cite this page